Cullinan Management

Compare

275 Followers

CGEM Stock Chart & Stats

$7.76

-$0.28(-2.38%)

At close: Jan 08 4:00 PM EST

$7.76

-$0.28(-2.38%)

Day’s Range― - ―

52-Week Range$5.68 - $17.50

Previous CloseN/A

Volume73.34K

Average Volume (3M)1.21M

Market Cap

$458.42M

Enterprise Value$180.42M

Total Cash (Recent Filing)$265.48M

Total Debt (Recent Filing)$1.52M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Nov 06, 2025

EPS Estimate

-0.95

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.07

Shares Outstanding59,074,390

10 Day Avg. Volume1,285,892

30 Day Avg. Volume1,214,758

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)1.11

Price to Sales (P/S)0.00

P/FCF Ratio-4.51

Enterprise Value/Market Cap0.39

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-589.61

Enterprise Value/Ebitda-0.77

Forecast

1Y Price Target

$26.71

Price Target Upside244.20% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Accelerated Approval PotentialThere is a high chance for accelerated approval of zipalertinib based on the Phase 2b data as there is currently no standard of care for +2L NSCLC patients with EGFR exon20ins.

Market PenetrationThere is potential for high market penetration for brain-penetrating drugs.

Regulatory MilestonesCullinan is eligible to receive up to $130 million in payments for EGFRex20 NSCLC U.S. regulatory milestones.

Bears Say

Competition ChallengesDizal's Zegfrovy showed no CNS responses at the approved FDA dose, highlighting competition challenges.

FDA Approval RiskInability to receive FDA approval is a risk factor for the company.

Trial Enrollment RisksRisks include, but are not limited to: slower-than-expected enrollment in the Phase 3 REZILIENT3 trial and negative zipalertinib or CLN-978 efficacy data.

Cullinan Management News

Promising Clinical Trial Results and Strategic Partnerships Drive Buy Rating for Cullinan Management

Morgan Stanley analyst Sean Laaman has maintained their bullish stance on CGEM stock, giving a Buy rating yesterday....

8d ago

CGEM

Buy Rating for Cullinan Management’s Zipalertinib: Promising Efficacy in Challenging EGFR Mutated NSCLC Cases

JonesTrading analyst Soumit Roy maintained a Buy rating on Cullinan Management today and set a price target of...

9d ago

CGEM

Promising Efficacy of Zipalertinib in EGFR NSCLC with CNS Involvement Justifies Buy Rating for Cullinan Management

Analyst Julian Harrison from BTIG maintained a Buy rating on Cullinan Management and keeping the price target at...

14d ago

CGEM

Promising Developments in Cullinan Management’s Zipalertinib Drive Buy Rating

Cullinan Management, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from...

15d ago

CGEM

Promising Trial Results and Strategic Plans Justify Buy Rating for Cullinan Management

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cullinan Management today and set a price target...

2M ago

CGEM

Positive Buy Rating for Cullinan Management Driven by Promising Zipalertinib Trial Results in NSCLC with Uncommon EGFR Mutations

Cullinan Management, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from...

2M ago

CGEM

Promising Drug Pipeline and Strategic Collaborations Drive Buy Rating for Cullinan Management

William Blair analyst Matt Phipps has reiterated their bullish stance on CGEM stock, giving a Buy rating on...

2M ago

CGEM

Cullinan Management’s Strategic Adjustments and Pipeline Development Justify Buy Rating

Leerink Partners analyst Andrew Berens has maintained their bullish stance on CGEM stock, giving a Buy rating on...

2M ago

CGEM

3 ‘Strong Buy’ Biotech Stocks Top Analysts Believe Have Over 300% Upside

Wall Street analysts don’t hand out “Strong Buy” ratings lightly. When they do, it usually means they’re convinced...

2M ago

CGEM

TECX

Promising Potential of Cullinan Management’s CLN-978 Therapy Drives Buy Rating

Analyst Julian Harrison from BTIG reiterated a Buy rating on Cullinan Management and keeping the price target at...

2M ago

CGEM

Cullinan Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $24 price target The company...

2M ago

CGEM

Cullinan has positive read from Novartis data, says Clear Street

After Novartis (NVS) announced that both of two Phase 3 trials evaluating ianalumab in adults with active Sjogren’s...

3M ago

NVS

CGEM

Cullinan Therapeutics reports Q2 EPS ($1.07), consensus (86c)

“I am proud of the team’s strong execution throughout the first half of the year as we continue...

3M ago

CGEM

Cullinan Therapeutics management to meet virtually with Clear Street

Virtual Meeting to be held on July 30 hosted by Clear Street. Published first on TheFly – the...

3M ago

CGEM

CGEM FAQ

What was Cullinan Management’s price range in the past 12 months?

Cullinan Management lowest stock price was $5.68 and its highest was $17.50 in the past 12 months.

What is Cullinan Management’s market cap?

Cullinan Management’s market cap is $458.42M.

When is Cullinan Management’s upcoming earnings report date?

Cullinan Management’s upcoming earnings report date is Nov 06, 2025 which is in 9 days.

How were Cullinan Management’s earnings last quarter?

Cullinan Management released its earnings results on Aug 07, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.858 by -$0.212.

Is Cullinan Management overvalued?

According to Wall Street analysts Cullinan Management’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cullinan Management pay dividends?

Cullinan Management does not currently pay dividends.

What is Cullinan Management’s EPS estimate?

Cullinan Management’s EPS estimate is -0.95.

How many shares outstanding does Cullinan Management have?

Cullinan Management has 59,074,390 shares outstanding.

What happened to Cullinan Management’s price movement after its last earnings report?

Cullinan Management reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.858. Following the earnings report the stock price went down -10.787%.

Which hedge fund is a major shareholder of Cullinan Management?

Currently, no hedge funds are holding shares in CGEM

Cullinan Management Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.01%

Trailing 12-Months

Asset Growth

-23.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cullinan Management

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Management (CGEM) Earnings & Revenues

Historic Earnings Reports

CGEM Stock 12 Month Forecast

Average Price Target

$26.71

▲(244.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","35":"$35","12.5":"$12.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.5,20,27.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,8.153846153846153,10.307692307692307,12.461538461538462,14.615384615384615,16.769230769230766,18.923076923076923,21.076923076923077,23.23076923076923,25.384615384615383,27.538461538461537,29.69230769230769,31.846153846153847,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,7.593076923076923,9.186153846153847,10.779230769230768,12.372307692307693,13.965384615384615,15.558461538461538,17.15153846153846,18.744615384615386,20.337692307692308,21.93076923076923,23.523846153846154,25.116923076923076,{"y":26.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,7.230769230769231,8.461538461538462,9.692307692307693,10.923076923076923,12.153846153846153,13.384615384615385,14.615384615384617,15.846153846153847,17.076923076923077,18.307692307692307,19.53846153846154,20.76923076923077,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >